Skip to main content
. 2024 Apr 19;18(2):101345. doi: 10.1016/j.jcmgh.2024.04.002

Table 5.

List of Fine-Mapped Credible Variants That Are Near Regulatory Sites Based on Ensembl Variation Annotation

Lead SNP Credible SNP Biotype CHR BP EA OA EAF GWAS
IBS subtype OR (95% CI) P
rs6899057
ADCY2
rs4286635 Enhancer 5 7242559 A C 0.60 IBS 0.94 (0.92–0.96) 2.0E-08
rs4286635 Enhancer 5 7242559 A C 0.60 IBS-M 0.92 (0.90–0.94) 4.1E-08
rs7718889 CTCF binding site 5 7200526 A T 0.63 IBS 0.94 (0.92–0.96) 2.1E-08
rs7718889 CTCF binding site 5 7200526 A T 0.63 IBS-M 0.92 (0.90–0.94) 2.1E-08
rs2048419
CLDN23 / MFHAS1
rs1039915 Enhancer 8 8679614 T C 0.53 IBS-M 1.07 (1.05–1.09) 2.3E-07
rs1039916 Enhancer 8 8685854 A G 0.52 IBS-M 1.07 (1.05–1.09) 2.7E-07
rs1039917 Enhancer 8 8718850 A G 0.37 IBS-M 0.93 (0.91–0.95) 9.6E-07
rs11775523 Enhancer 8 8679176 A G 0.53 IBS-M 1.07 (1.05–1.09) 2.7E-07
rs11992186 CTCF binding site 8 8524474 C G 0.49 IBS-M 1.07 (1.05–1.09) 1.4E-06
rs13270070 Enhancer 8 8691622 A T 0.44 IBS-M 0.93 (0.91–0.95) 1.4E-06
rs13282015 Enhancer 8 8659675 T G 0.76 IBS-M 0.92 (0.88–0.96) 3.4E-06
rs2409092 Enhancer 8 8682192 A T 0.53 IBS-M 1.07 (1.05–1.09) 1.5E-07
rs332039 Enhancer 8 8723651 C G 0.57 IBS-M 1.07 (1.05–1.09) 1.8E-06
rs35039922 Enhancer 8 8675325 A T 0.53 IBS-M 1.07 (1.05–1.09) 2.4E-07
rs35900578 Enhancer 8 8719513 A G 0.40 IBS-M 0.93 (0.91–0.95) 4.7E-07
rs3789843 Enhancer 8 8724257 T C 0.41 IBS-M 0.93 (0.91–0.95) 3.7E-07
rs3789845 Enhancer 8 8723918 T G 0.34 IBS-M 0.93 (0.91–0.95) 1.0E-06
rs3789849 Enhancer 8 8687054 C G 0.43 IBS-M 0.93 (0.91–0.95) 3.0E-07
rs3827806 Enhancer 8 8724276 T C 0.41 IBS-M 0.93 (0.91–0.95) 3.8E-07
rs4840362 Enhancer 8 8670082 C G 0.46 IBS-M 0.93 (0.91–0.95) 1.4E-07
rs4841040 Promoter 8 8654527 T C 0.53 IBS-M 1.08 (1.06–1.10) 7.8E-08
rs4841042 Enhancer 8 8664622 A G 0.46 IBS-M 0.93 (0.91–0.95) 1.4E-07
rs4841051 Enhancer 8 8685646 T C 0.52 IBS-M 1.07 (1.05–1.09) 2.2E-07
rs560544 CTCF binding site 8 8637429 A G 0.52 IBS-M 1.07 (1.05–1.09) 3.7E-07
rs56367294 Enhancer 8 8722527 A G 0.32 IBS-M 0.93 (0.89–0.97) 1.4E-06
rs60315134 Enhancer 8 8670599 A G 0.54 IBS-M 1.07 (1.05–1.09) 1.9E-07
rs7820146 Enhancer 8 8699757 A T 0.44 IBS-M 0.93 (0.91–0.95) 6.1E-07
rs7823757 Enhancer 8 8670177 A T 0.46 IBS-M 0.93 (0.91–0.95) 1.6E-07
rs7833171 Enhancer 8 8699761 T C 0.44 IBS-M 0.93 (0.91–0.95) 5.8E-07
rs882462 Enhancer 8 8678530 A G 0.47 IBS-M 0.93 (0.91–0.95) 3.5E-07
rs2035380
BMAL1
rs10766064 Open chromatin region 11 13277932 A G 0.74 IBS 0.94 (0.92–0.96) 5.7E-07
rs10766065 Open chromatin region 11 13277961 T C 0.72 IBS 0.94 (0.92–0.96) 9.4E-07
rs10766066 Open chromatin region 11 13278027 A G 0.72 IBS 0.94 (0.92–0.96) 9.4E-07
rs10832018 Enhancer 11 13312424 A G 0.71 IBS 0.94 (0.92–0.96) 8.9E-08
rs10832021 Enhancer 11 13324530 A G 0.71 IBS 0.94 (0.92–0.96) 5.2E-07
rs11022733 Enhancer 11 13281557 A C 0.71 IBS 0.94 (0.92–0.96) 8.3E-07
rs11022734 Enhancer 11 13281580 A G 0.29 IBS 1.06 (1.04–1.08) 8.3E-07
rs11022735 Enhancer 11 13292727 A C 0.30 IBS 1.06 (1.04–1.08) 7.8E-08
rs11022743 Promoter 11 13297800 A G 0.27 IBS 1.06 (1.04–1.08) 5.7E-07
rs11022753 CTCF binding site 11 13310854 T C 0.73 IBS 0.94 (0.92–0.96) 7.8E-07
rs11022754 Enhancer 11 13313243 A G 0.27 IBS 1.06 (1.04–1.08) 7.3E-07
rs11022756 Enhancer 11 13315439 A C 0.29 IBS 1.06 (1.04–1.08) 8.9E-08
rs11022757 Enhancer 11 13322580 A G 0.29 IBS 1.06 (1.04–1.08) 5.5E-07
rs11605776 Enhancer 11 13318524 A C 0.71 IBS 0.94 (0.92–0.96) 4.1E-07
rs12290622 Enhancer 11 13314307 A G 0.71 IBS 0.94 (0.92–0.96) 8.5E-08
rs12361893 Promoter 11 13301114 C G 0.30 IBS 1.06 (1.04–1.08) 1.5E-07
rs1351525 Promoter 11 13301548 A T 0.29 IBS 1.06 (1.04–1.08) 1.5E-07
rs1384030 Enhancer 11 13292909 T C 0.30 IBS 1.06 (1.04–1.08) 8.3E-08
rs1481891 CTCF binding site 11 13310718 T C 0.29 IBS 1.06 (1.04–1.08) 8.7E-08
rs1481892 Promoter 11 13301921 C G 0.71 IBS 0.94 (0.92–0.96) 1.5E-07
rs2035380 Enhancer 11 13284345 T C 0.30 IBS 1.07 (1.04–1.09) 3.1E-08
rs2219998 Enhancer 11 13292864 A G 0.57 IBS 0.94 (0.92–0.96) 1.8E-07
rs2279284 Promoter 11 13298750 T C 0.27 IBS 1.06 (1.04–1.08) 5.3E-07
rs2279285 Promoter 11 13298687 T G 0.70 IBS 0.94 (0.92–0.96) 9.4E-08
rs2279286 Promoter 11 13298519 A G 0.70 IBS 0.94 (0.92–0.96) 8.4E-08
rs2279287 Promoter 11 13298485 T C 0.30 IBS 1.06 (1.04–1.08) 8.4E-08
rs2403661 Enhancer 11 13285281 T G 0.30 IBS 1.07 (1.05–1.09) 3.6E-08
rs34148132 Enhancer 11 13314475 T C 0.29 IBS 1.06 (1.04–1.08) 8.2E-08
rs34796300 Enhancer 11 13315205 T C 0.43 IBS 1.06 (1.04–1.08) 2.9E-07
rs4603287 Promoter 11 13301335 T G 0.29 IBS 1.06 (1.04–1.08) 1.5E-07
rs4757138 Promoter 11 13297925 A G 0.30 IBS 1.06 (1.04–1.08) 8.8E-08
rs4757139 Promoter 11 13300456 T C 0.70 IBS 0.94 (0.92–0.96) 1.3E-07
rs4757140 Promoter 11 13300540 T G 0.70 IBS 0.94 (0.92–0.96) 1.4E-07
rs55769038 Enhancer 11 13331808 A G 0.59 IBS 0.94 (0.92–0.96) 6.1E-07
rs61882122 Promoter 11 13299895 A G 0.30 IBS 1.06 (1.04–1.08) 9.7E-08
rs6486116 CTCF binding site 11 13319838 A C 0.29 IBS 1.06 (1.04–1.08) 6.3E-07
rs6486118 Enhancer 11 13323786 A G 0.71 IBS 0.94 (0.92–0.96) 4.0E-07
rs6486119 Enhancer 11 13323789 T C 0.29 IBS 1.06 (1.04–1.08) 4.3E-07
rs6486120 Enhancer 11 13324142 T G 0.29 IBS 1.06 (1.04–1.08) 5.1E-07
rs7114573 Enhancer 11 13323498 A C 0.29 IBS 1.06 (1.04–1.08) 5.2E-07
rs7125487 Enhancer 11 13282058 C G 0.28 IBS 1.07 (1.05–1.09) 1.3E-07
rs72867447 Promoter 11 13301875 C G 0.43 IBS 1.06 (1.04–1.08) 3.3E-07
rs7928655 Promoter 11 13300252 C G 0.30 IBS 1.06 (1.04–1.08) 8.7E-08
rs7937432 CTCF binding site 11 13320525 A G 0.71 IBS 0.94 (0.92–0.96) 4.1E-07
rs7938307 CTCF binding site 11 13320526 A C 0.71 IBS 0.94 (0.92–0.96) 3.7E-07
rs7949336 CTCF binding site 11 13319894 A G 0.74 IBS 0.94 (0.92–0.96) 7.6E-07
rs7951393 Enhancer 11 13318431 T C 0.71 IBS 0.94 (0.92–0.96) 4.7E-07
rs998089 Enhancer 11 13284111 T C 0.27 IBS 1.06 (1.04–1.08) 4.5E-07
rs9517497
DOCK9
rs6491472 Enhancer 13 99598367 A G 0.37 IBS 0.94 (0.92–0.96) 3.1E-08
rs7337807 Enhancer 13 99610581 A C 0.63 IBS 1.06 (1.04–1.08) 3.8E-08
rs7338982 Enhancer 13 99610373 T C 0.63 IBS 1.06 (1.04–1.08) 3.6E-08
rs7339076 Enhancer 13 99599128 C G 0.63 IBS 1.06 (1.04–1.08) 4.1E-08
rs7987680 Enhancer 13 99601519 T G 0.63 IBS 1.06 (1.04–1.08) 4.7E-08
rs9513513 Open chromatin region 13 99595622 T C 0.63 IBS 1.06 (1.04–1.08) 2.4E-08
rs9517497 Open chromatin region 13 99594953 T C 0.63 IBS 1.07 (1.04–1.09) 2.3E-08
rs9517502 Enhancer 13 99599727 A C 0.37 IBS 0.94 (0.92–0.96) 4.5E-08
rs9517503 Enhancer 13 99600658 A G 0.63 IBS 1.06 (1.04–1.08) 4.6E-08
rs9517508 Enhancer 13 99606192 T G 0.37 IBS 0.94 (0.92–0.96) 5.2E-08
rs9557097 Enhancer 13 99612588 T C 0.62 IBS 1.06 (1.04–1.08) 9.4E-08

NOTE. Functional consequence of variants was performed using the Ensembl Variant Effect Predictor tool (https://grch37.ensembl.org/info/docs/tools/vep). OR: mean effects described to the risk allele in the meta-analysis.

BP, base-pair position (genome build hg19); CHR, chromosome; CI, confidence interval; EA, effect allele; EAF, effect allele frequency; GWAS, genome-wide association study; IBS, irritable bowel syndrome; IBS-M, irritable bowel syndrome mixed subtype; LL, Lifelines; OA, other allele; OR, odds ratio; SNP, single-nucleotide polymorphism; UKBB, UK Biobank.